WallStreetZenWallStreetZen

NASDAQ: NUVA
Nuvasive Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for NUVA

Based on 13 analysts offering 12 month price targets for Nuvasive Inc.
Min Forecast
$44.50+20.01%
Avg Forecast
$52.29+41.01%
Max Forecast
$62.00+67.21%

Should I buy or sell NUVA stock?

Based on 13 analysts offering ratings for Nuvasive Inc.
Buy
Strong Buy
3 analysts 23.08%
Buy
2 analysts 15.38%
Hold
8 analysts 61.54%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their NUVA stock forecasts and price targets.

NUVA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
JP Morgan
Top 33%
68
HoldMaintains$45.00+21.36%2023-02-23
Morgan Stanley
Bottom 22%
22
HoldMaintains$44.50+20.01%2023-02-23
Wells Fargo
Bottom 47%
47
HoldDowngrades$57.72+55.66%2023-02-10
Truist Securities
Top 6%
95
HoldDowngrades$52.50+41.59%2023-02-10
Citigroup
Top 4%
97
HoldDowngrades$52.00+40.24%2023-02-10
RBC Capital
Bottom 19%
19
BuyMaintains$58.00+56.42%2022-11-10
Piper Sandler
Bottom 4%
4
Strong BuyMaintains$50.00+34.84%2022-11-10
Needham
Bottom 7%
7
BuyMaintains$52.00+40.24%2022-11-10
Barclays
Bottom 8%
8
Strong BuyInitiates Coverage On$53.00+42.93%2022-10-18
Jefferies
Top 14%
87
HoldInitiates Coverage On$45.00+21.36%2022-10-12

1 of 2

Forecast return on equity

Is NUVA forecast to generate an efficient return?
Company
19.82%
Industry
24.2%
Market
52.51%
NUVA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NUVA forecast to generate an efficient return on assets?
Company
7.74%
Industry
12.49%
NUVA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NUVA earnings per share forecast

What is NUVA's earnings per share in the next 3 years based on estimates from 7 analysts?
Avg 1 year Forecast
$2.52+223.08%
Avg 2 year Forecast
$2.97+280.77%
Avg 3 year Forecast
$3.30+323.08%
NUVA's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

NUVA revenue forecast

What is NUVA's revenue in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$1.3B+8.79%
Avg 2 year Forecast
$1.4B+16.23%
Avg 3 year Forecast
$1.5B+24.03%
NUVA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NUVA earnings growth forecast

How is NUVA forecast to perform vs Medical Devices companies and vs the US market?
Company
94.07%
Industry
57.81%
Market
26.86%
NUVA's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
NUVA's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
NUVA's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

NUVA revenue growth forecast

How is NUVA forecast to perform vs Medical Devices companies and vs the US market?
Company
7.85%
Industry
8.4%
Market
9.33%
NUVA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NUVA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NUVA vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
NUVA$37.08$52.29+41.01%Buy
AHCO$13.83$27.60+99.57%Strong Buy
ATEC$15.82$16.25+2.72%Strong Buy
ESTA$70.95$97.75+37.77%Strong Buy
LIVN$41.70$79.20+89.93%Buy
View Top Medical Device Stocks

Nuvasive Stock Forecast FAQ

Is Nuvasive Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 13 Wall Street analysts covering (NASDAQ: NUVA) stock is to Buy NUVA stock.

Out of 13 analysts, 3 (23.08%) are recommending NUVA as a Strong Buy, 2 (15.38%) are recommending NUVA as a Buy, 8 (61.54%) are recommending NUVA as a Hold, 0 (0%) are recommending NUVA as a Sell, and 0 (0%) are recommending NUVA as a Strong Sell.

If you're new to stock investing, here's how to buy Nuvasive stock.

What is NUVA's earnings growth forecast for 2023-2025?

(NASDAQ: NUVA) Nuvasive's forecast annual earnings growth rate of 94.07% is forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 57.81%, and and it is also forecast to beat the US market's average forecast earnings growth rate of 26.86%.

Nuvasive's earnings in 2023 is $40,407,000.On average, 7 Wall Street analysts forecast NUVA's earnings for 2023 to be $131,524,140, with the lowest NUVA earnings forecast at $123,695,322, and the highest NUVA earnings forecast at $135,699,509. On average, 3 Wall Street analysts forecast NUVA's earnings for 2024 to be $155,010,593, with the lowest NUVA earnings forecast at $152,400,987, and the highest NUVA earnings forecast at $157,098,278.

In 2025, NUVA is forecast to generate $172,233,993 in earnings, with the lowest earnings forecast at $172,233,993 and the highest earnings forecast at $172,233,993.

What is NUVA's revenue growth forecast for 2023-2025?

(NASDAQ: NUVA) Nuvasive's forecast annual revenue growth rate of 7.85% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.4%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.33%.

Nuvasive's revenue in 2023 is $1,201,942,000.On average, 5 Wall Street analysts forecast NUVA's revenue for 2023 to be $68,243,283,277, with the lowest NUVA revenue forecast at $67,622,197,061, and the highest NUVA revenue forecast at $68,904,035,504. On average, 3 Wall Street analysts forecast NUVA's revenue for 2024 to be $72,914,999,849, with the lowest NUVA revenue forecast at $72,900,386,056, and the highest NUVA revenue forecast at $72,941,095,908.

In 2025, NUVA is forecast to generate $77,807,489,084 in revenue, with the lowest revenue forecast at $77,807,489,084 and the highest revenue forecast at $77,807,489,084.

What is NUVA's forecast return on assets (ROA) for 2023-2025?

(NASDAQ: NUVA) forecast ROA is 7.74%, which is lower than the forecast US Medical Devices industry average of 12.49%.

What is NUVA's Price Target?

According to 13 Wall Street analysts that have issued a 1 year NUVA price target, the average NUVA price target is $52.29, with the highest NUVA stock price forecast at $62.00 and the lowest NUVA stock price forecast at $44.50.

On average, Wall Street analysts predict that Nuvasive's share price could reach $52.29 by Feb 23, 2024. The average Nuvasive stock price prediction forecasts a potential upside of 41.01% from the current NUVA share price of $37.08.

What is NUVA's Earnings Per Share (EPS) forecast for 2023-2025?

(NASDAQ: NUVA) Nuvasive's current Earnings Per Share (EPS) is $0.78. On average, analysts forecast that NUVA's EPS will be $2.52 for 2023, with the lowest EPS forecast at $2.37, and the highest EPS forecast at $2.60. On average, analysts forecast that NUVA's EPS will be $2.97 for 2024, with the lowest EPS forecast at $2.92, and the highest EPS forecast at $3.01. In 2025, NUVA's EPS is forecast to hit $3.30 (min: $3.30, max: $3.30).

What is NUVA's forecast return on equity (ROE) for 2023-2025?

(NASDAQ: NUVA) forecast ROE is 19.82%, which is considered weak.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.